Frederic Lagarce
Overview
Explore the profile of Frederic Lagarce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delaporte F, Roger E, Bejaud J, Loyer P, Lagarce F, Savary C
Int J Pharm
. 2024 Oct;
667(Pt A):124815.
PMID: 39424085
Lipid nanocapsules (LNCs) used as nanomedicine have been developed to enhance pharmacokinetics and decrease side effects of drugs, particularly for cancer therapies. After intravenous administration, LNCs possess an important hepatic...
2.
Sandler Topelius N, Shokraneh F, Bahman M, Lahtinen J, Hassinen N, Airaksinen S, et al.
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794340
Pharmacy compounding, the art and science of preparing customized medications to meet individual patient needs, is on the verge of transformation. Traditional methods of compounding often involve manual and time-consuming...
3.
Lebreton V, Legeay S, Rapenne C, Saulnier P, Lagarce F
Nanomedicine (Lond)
. 2024 May;
19(13):1123-1131.
PMID: 38690778
The present study investigated renal elimination after intravenous administration of four different formulations of lipid nanocapsules (LNCs) containing dyes adapted to Förster resonance energy transfer (FRET-LNCs). FRET-LNCs of 85 or...
4.
Lebreton V, Legeay S, Vasylaki A, Lagarce F, Saulnier P
Eur J Pharm Sci
. 2023 Jul;
189:106537.
PMID: 37490974
The parameters currently used for characterization of nanoparticles, such as size and zeta potential, were not able to reflect the performance of a nanocarrier in the biological environment. Therefore, more...
5.
Lebreton V, Kaeokhamloed N, Vasylaki A, Hilairet G, Mellinger A, Bejaud J, et al.
J Control Release
. 2022 Oct;
351:681-691.
PMID: 36191672
The present study investigated the pharmacokinetics of intact lipid nanocapsules (LNCs) after intravenous administration in rats. Six different Förster resonance energy transfer LNCs (FRET-LNCs) have been studied with 2 sizes...
6.
Bourcier B, Lagarce F, Lebreton V
J Pharm Biomed Anal
. 2022 Jan;
210:114543.
PMID: 34991044
Idarubicin (IDA) is an antineoplasic drug commonly used to treat hematologic diseases. Because of its relative lipophilic properties, this anthracycline is also used in transarterial chemoembolization (TACE) as part of...
7.
Lebreton V, Legeay S, Saulnier P, Lagarce F
Drug Discov Today
. 2021 Apr;
26(10):2259-2268.
PMID: 33892140
Nanomedicines have been developed for more than four decades to optimize the pharmacokinetics (PK) of drugs, especially absorption, distribution, and stability in vivo. Unfortunately, only a few drug products have...
8.
Annweiler C, Lagarce F, Lerolle N
Clin Teach
. 2020 Oct;
18(3):224-225.
PMID: 33103354
No abstract available.
9.
10.
Briot T, Roger E, Bou Haidar N, Bejaud J, Lautram N, Guillet C, et al.
Int J Nanomedicine
. 2019 Apr;
14:2091-2102.
PMID: 30988610
Background: Acute myeloid leukemia mainly affects adult patients. Complete remission for patients younger than 60 years, who are candidates for standard induction therapy, is achieved in 60%-80% of cases. However,...